Publications by authors named "A M Krackhardt"
Neoantigen-specific T cell receptors (neoTCRs) promise safe, personalized anti-tumor immunotherapy. However, detailed assessment of neoTCR-characteristics affecting therapeutic efficacy is mostly missing. Previously, we identified diverse neoTCRs restricted to different neoantigens in a melanoma patient.
View Article and Find Full Text PDFArticle Synopsis
- Systemic pan-tumor analyses help uncover key features related to cancer immune response and patient outcomes across different tumor types.
- A study involving 32 patients and 25 tumor types employed multi-omics data to discover various tumor-specific neoantigens using an optimized computational pipeline that integrates DNA/RNA sequencing and mass spectrometry.
- The research highlights the significance of RNA data in identifying potential neoantigens, revealing 32 promising candidates linked to RNA-identified variants, thereby emphasizing the need for further exploration in this area.
Background: BCMA-directed CAR T-cell therapy (CAR-T) has altered the treatment landscape of relapsed/refractory (r/r) multiple myeloma, but is hampered by unique side effects that can lengthen hospital stays and increase morbidity. Hematological toxicity (e.g.
View Article and Find Full Text PDFAdoptive cell therapy (ACT) has seen a steep rise of new therapeutic approaches in its immune-oncology pipeline over the last years. This is in great part due to the recent approvals of chimeric antigen receptor (CAR)-T cell therapies and their remarkable efficacy in certain soluble tumors. A big focus of ACT lies on T cells and how to genetically modify them to target and kill tumor cells.
View Article and Find Full Text PDF